TGFBR1 and hepatocellular carcinoma: The sole TGF-β pathway inhibitor undergoing clinical testing in HCC patients is galunisertib (LY2157299), a selective ATP mimetic inhibitor of TGF-RI/ALK5 (NCT01246986).